---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-125418"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:18:39.151330+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports FY 2025 net loss of $24.8M; launches LYMPHIR in U.S.

## Summary
- Net loss of $24.8M ($0.34 per share) vs $21.1M ($0.31) in FY 2024, driven by pre-commercial investment.
- Cash and equivalents $3.9M as of Sep 30, 2025; raised $36M in three financings post- and intra-year.
- LYMPHIR launched in U.S. Dec 2025; distribution agreements with top three wholesalers secured.
- International access via Named Patient Programs in 19 markets; collaboration with Verix for AI-driven commercial targeting.
- R&D expense $6.4M (up from $4.9M); G&A $8.8M ($8.1M prior); stock-based comp $8.3M ($7.5M).

## SEC filing metadata
- accession: 0001213900-25-125418
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/0001213900-25-125418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/ea0270775-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-125418
- JSON: https://secwatch.observer/filing/0001213900-25-125418.json
- Plain text: https://secwatch.observer/filing/0001213900-25-125418.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.